Hugel said on the 11th that last year's operating profit on a consolidation basis was 201.6 billion won, up 21.3% from a year earlier. Revenue for the same period rose 14% to 425.1 billion won, the highest on record.
Hugel's fourth-quarter revenue last year was 119.1 billion won, and operating profit was 58.6 billion won, up 21.3% and 26.2%, respectively, from a year earlier. The quarterly results also maintained a solid growth trajectory.
The performance growth was driven by expanded overseas sales of the botulinum toxin "Botulax" (overseas product name Letibbo), the hyaluronic acid (HA) filler "The Chaeum" (Revolax, etc.), and "Byryzn." Growth of the cosmetics brands "Wellage" and "Byryzn BR" also contributed.
By product, annual revenue was ▲ toxin 233.8 billion won (up 15% year over year) ▲ filler 129.7 billion won (up 1.7%) ▲ cosmetics and others 61.6 billion won (up 45.9%). In particular, combined sales of toxin and filler increased 10% to 363.5 billion won. Of that, overseas sales were 268.5 billion won, up 22%, leading the growth.
The export share of the two items also expanded. The export share, which was 66% in 2024, rose to 74% in 2025.
By region, growth was notable in the North and South American markets, including the United States and Brazil. Combined toxin and filler sales in the region were 67.9 billion won, up 105% from a year earlier. Fourth-quarter revenue was 29.2 billion won, a surge of about 310% from the same period a year earlier.
Hugel plans to pursue both scale expansion and profitability improvement, focusing on the United States, the world's largest toxin market. Starting this year, it will fully operate a "hybrid sales model" that combines partner distribution with direct sales to expand local market share.
Hugel Global Chief Executive Officer (CEO) Carrie Strom said, "Based on solid global competitiveness, we achieved our first-ever revenue in the 400 billion-won range," adding, "This year, we will further strengthen our mid- to long-term growth foundation, focusing on the global big four markets of the United States, China, Europe, and Brazil."